When Risudil Meets Dry Macular Degeneration: A New Breakthrough in Overcoming the Incurable Dilemma
Share
🌌 When 67-year-old Professor Zhang put down his microscope, a black hole suddenly appeared in the center of his field of vision—a shared nightmare for 210 million patients with dry macular degeneration (dAMD) : without a cure, they can only watch helplessly as their vision is eroded. Until May 2025, a groundbreaking AI-driven discovery unexpectedly made risudil hydrochloride, a commonly used glaucoma medication, a new hope in the fight against dAMD.
Dry age-related macular degeneration (dAMD) accounts for more than 90% of all AMD cases , affecting over 200 million people worldwide. It is characterized by the degeneration of retinal pigment epithelial (RPE) cells, leading to progressive death of photoreceptors and ultimately resulting in geographic atrophy (GA)—like a sprawling "desert" on the retina, permanently obliterating vision wherever it spreads . Even more devastatingly, previously no oral or ophthalmic medication could stop the spread of GA ; approved complement inhibitors required monthly intraocular injections and could only slow lesion progression by 30%.
Today, risudil, a ROCK inhibitor that was once used to treat glaucoma, is using the "insight" of AI scientists to embark on a groundbreaking journey in the treatment of dAMD.
01 How AI Breaks Through Human Blind Spots: Rewriting the History of dAMD Treatment in 2.5 Months
🔍 A Cross-Disciplinary Insight from Glaucoma to Macular Degeneration
In May 2025, Robin, a multi-agent system from FutureHouse Labs , made a groundbreaking discovery that shook the academic world:
● Phase 1 : Robin used the Crow agent to analyze 151 articles and identified " RPE cell phagocytic dysfunction " as the core pathology of dAMD—these cells should clear the outer segment disc membrane shed by photoreceptor cells, and functional decline will lead to the accumulation of toxic lipids.
● Phase 2 : Through Falcon evaluation of 400+ papers, 30 candidate drugs that may enhance RPE phagocytosis function were screened. The first round of laboratory validation showed that the ROCK inhibitor Y-27632 was significantly effective.
● Stage 3 : RNA sequencing revealed that Y-27632 upregulated ABCA1 gene expression by 3-fold —this gene encodes a lipid efflux pump, which is key to maintaining RPE health.
● Breakthrough : In iterative experiments, Robin discovered that the phagocytic enhancement effect of the glaucoma drug Ripasudil was 7.5 times that of Y-27632 , and its biosafety has been clinically validated for many years.
💡 This discovery is revolutionary because previous dAMD research focused on complement pathways or antioxidants, while the novel targeting pathway of the ROCK-RPE-ABCA1 axis opens up a new dimension for treatment.
02 Risudil's Triple Mechanism of Action: From Cytoskeleton to Gene Regulation
⚙️ Mechanism 1: Remodeling the cytoskeleton and activating the "cleaner" function
● Risudil relaxes actin fibers in RPE cells by inhibiting Rho kinase (ROCK), making the cells more flexible and able to wrap around the outer segment disc membrane.
● Experiments showed that RPE cells treated with risudil exhibited a 2.3-fold increase in phagocytic cup formation rate and a 7.5-fold increase in phagocytic efficiency compared to the control group.
🧬 Mechanism 2: Activating the ABCA1 gene to clear "metabolic waste".
● RNA sequencing confirmed that risudil significantly upregulated ABCA1 transporter expression (corrected p-value = 2.13 × 10⁻⁸³).
● ABCA1, as a key pump for reverse cholesterol transport , can carry lipids accumulated in the RPE to high-density lipoprotein, preventing the formation of lipofuscin—the culprit behind GA development.
🛡️ Mechanism 3: Inhibiting mitochondrial apoptosis and protecting the cell's energy station
● Recent animal experiments have shown that risudil can reduce the BAX/Bcl-2 ratio , a factor associated with apoptosis in RPE cells, and maintain mitochondrial membrane potential.
● This has synergistic potential with Elamipretide (Stealth Bio), a mitochondrial targeted drug that entered Phase III trials in March 2025.
Molecular interaction diagram
Risudil → Inhibits ROCK kinase
→ Actin depolymerization → Enhanced phagocytic cup formation → Clearance of outer segmental disc membranes
→ Upregulates ABCA1 expression → Promotes lipid efflux → Reduces lipofuscin deposition
→ Stabilizes mitochondrial membrane potential → Inhibits RPE cell apoptosis
03 Horizontal Comparison: Why Risudil May Reshape the Treatment Landscape
💉 A disruptive breakthrough compared to existing therapies: oral vs. injectable.
|
Types of therapy |
Representative drugs |
GA progression inhibition rate |
Administration method |
Main limitations |
|
complement inhibitors |
Syfovre/Izervay |
28%-36% |
Monthly intraocular injections |
Risk of retinal detachment (>5%) |
|
antioxidants |
AREDS2 formula |
No significant evidence |
Oral administration daily |
Only applicable to the early stages |
|
ROCK inhibitors |
Lishudiil |
Animal models 55% |
Daily eye drops |
No non-human primate data available. |
|
stem cell therapy |
MA09-hRPE |
Phase I/II is underway |
Subretinal implantation |
Immune rejection risk |
Note: Risudil data is sourced from the 2025 AI Lab Mouse Model Report.
💎 Core Advantages Analysis
● Non-invasive drug delivery : Avoids the pain and infection risks of monthly intraocular injections.
● Dual-target synergistic effect : Simultaneously improves RPE phagocytic function and lipid metabolism, while complement inhibitors only block a single inflammatory pathway.
● Safety Accumulation : It has been used in Japan for over 10 years as a glaucoma medication, and its systemic safety profile is well-established.
04 Clinical Translation Roadmap: The Essential Path from Lab to Shelf
⏳ Current research stage
● Preclinical : Cell and animal experiments confirmed the mechanism of enhanced RPE phagocytosis and ABCA1 upregulation.
● Phase I Preparation : The dose exploration trial is expected to begin in 2026, with a focus on monitoring corneal endothelial safety (previous reports indicate 0.7% transient edema).
05 Scientific Intervention Plan: Proactive Defense Strategies for High-Risk Groups
🧭 dAMD Risk Self-Assessment Table
If any three of the following conditions are met , macular protection should be initiated immediately:
☑️ Age ≥ 55 years old
☑️ Family history of AMD
☑️ Smoking history (currently smoking or quitting smoking < 5 years)
☑️ Dyslipidemia (LDL > 3.4 mmol/L)
☑️ Fundus examination revealed moderate to large drusen.
💡 Joint Intervention Matrix
● Early dAMD (AREDS score 2-3) :
○ Morning: AREDS2 formula (10mg lutein + 2mg zeaxanthin)
○ Midday: 0.4% Risudil eye drops (press on the lacrimal sac area for 1 minute to prevent systemic absorption)
○ Before bedtime: Resveratrol 100mg (inhibits inflammasome activation)
● Mid-term dAMD (with focal GA) :
Monthly : Complement inhibitor injection (Syfovre/Izervay)
○ Twice daily: Sodium hyaluronate (Lisudil) (≥2 hours apart from injection)
⚠️ Contraindications : Avoid using eye drops containing dexamethasone (may induce high intraocular pressure), and use strong vasoconstrictors with caution (as they may exacerbate retinal ischemia).
🏆 Asakusa Cosmetics provides you with
✔️ Genuine Lisudil Hydrochloride
✔️ Hospital prescription
✔️ Online doctor consultation
✔️ Pharmacist's Medication Instructions
✔️ Comprehensive after-sales tracking service
⚠️ Friendly reminder: This article is for reference only. Please consult your doctor for specific medication advice.
-------------------------------------------------------------------------------------------------
📞Welcome to scroll down to contact customer service, purchase online, and have it shipped directly to your door.